Among the above mentioned 528 participants, a total of 240 participants who received the full panel of tumor marker test including CEA, CA125, CYFRA21-1, SCC, and NSE before therapy were allocated to an expansion phase to compare the diagnostic performance of the lncRNAs with tumor protein markers (Figure 1). The gene discussed is CEACAM5; the disease is neoplasm.